<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462304</url>
  </required_header>
  <id_info>
    <org_study_id>END-DME1</org_study_id>
    <nct_id>NCT02462304</nct_id>
  </id_info>
  <brief_title>To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema</brief_title>
  <acronym>END-DME</acronym>
  <official_title>To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nagoya City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asahikawa Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Fukui</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eguchi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagasaki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Medical University Hachioji Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hokkaido University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyorin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Cheon Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yamagata University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      To compare the efficacy of monotherapy with anti-Vascular Endothelial Growth Factor&#xD;
      (ranibizumab or bevacizumab) with combined therapy with anti-Vascular Endothelial Growth&#xD;
      Factor and end-point-management grid laser photocoagulation for diabetic macular edema.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Open-label non-randomized interventional study.&#xD;
&#xD;
      Study overview:&#xD;
&#xD;
      This study aims to look at the efficacy of treating diabetic macular edema (DME) with either&#xD;
      anti-Vascular Endothelial Growth Factor(anti-VEGF) monotherapy, compared with combination&#xD;
      therapy with anti-VEGF and End-Point-Management (EPM) grid laser photocoagulation, over a&#xD;
      period of 6 months.&#xD;
&#xD;
      Various sites from across Asia (Japan, South Korea, Hong Kong) will participate. Depending on&#xD;
      the availability of EPM laser, sites can either contribute to the 'Anti-VEGF monotherapy'&#xD;
      arm, or to the 'Combination therapy' arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in number of anti-VEGF required</measure>
    <time_frame>6 months</time_frame>
    <description>The number of injections of anti-VEGF required at the end of the 6 months period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>The change in best corrected visual acuity among subjects in different groups at the end of the 6 months period when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>6 months</time_frame>
    <description>The change in central retinal thickness among subjects in different groups at the end of the 6 months period when compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of changes in intraocular pressure post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related complications</measure>
    <time_frame>6 months</time_frame>
    <description>This will look at treatment related complications in terms of retinal detachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of macular edema</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence of macular edema during the 6 months period will be monitored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Macula Edema</condition>
  <arm_group>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive both anti-VEGF injections and EPM laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive anti-VEGF injections monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>End-Point-Management grid laser</intervention_name>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Anti-VEGF monotherapy</arm_group_label>
    <arm_group_label>Combination Anti-VEGF and EPM laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years with CSME&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus (type 1 or type 2)&#xD;
&#xD;
          -  At least one eye meets the study eye criteria&#xD;
&#xD;
          -  Able and willing to provide informed consent prior to any study-related procedures&#xD;
&#xD;
          -  Central foveal thickness ≥ 300 microns at baseline (SPECTRALIS or Cirrus HD OCT)&#xD;
&#xD;
          -  LogMAR Best corrected visual acuity 0.20 (Snellen 20/30) to 1.3 (Snellen 20/400).&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Central Foveal Thickness on OCT 300-600 micron&#xD;
&#xD;
          -  After first injection, wait for ME to reduce before proceeding with the laser. Exclude&#xD;
             if ME persists &gt;500um at the 4-week follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema is considered to be due to a cause other than diabetic macular edema.&#xD;
&#xD;
          -  An ocular condition is present such that, in the opinion of the investigator, visual&#xD;
             acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy,&#xD;
             VMT, pigment epithelium abnormalities, dense subfoveal hard exudates, non-retinal&#xD;
             condition such as glaucoma etc).&#xD;
&#xD;
          -  Substantial cataract that, in the opinion of the investigator, is likely to be&#xD;
             affecting visual acuity. Likely to be affecting BCVA and performing laser treatment.&#xD;
&#xD;
          -  History of treatment for diabetic macular edema at any time in the past (such as grid&#xD;
             macular photocoagulation).&#xD;
&#xD;
          -  History of treatment for diabetic macular edema at any time in the past 3 months (such&#xD;
             as intravitreal or peribulbar corticosteroids, ranibizumab, bevacizumab, aflibercept).&#xD;
&#xD;
          -  Focal laser photocoagulation should be performed before enrolling into the study if&#xD;
             needed. 3 months gap required between last laser procedure and recruitment.&#xD;
&#xD;
          -  History of panretinal (scatter) photocoagulation (PRP) within 3 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Anticipated need for PRP in the study period.&#xD;
&#xD;
          -  History of major retinal surgery (including vitrectomy, scleral buckle, any glaucoma&#xD;
             surgery, etc.).&#xD;
&#xD;
          -  History of YAG capsulotomy performed within 3 months.&#xD;
&#xD;
          -  Aphakia.&#xD;
&#xD;
          -  Intraocular pressure ≥ 25 mmHg.&#xD;
&#xD;
          -  History of open-angle glaucoma (either primary open-angle glaucoma or other cause of&#xD;
             open-angle glaucoma; note: history of angle-closure glaucoma is not an exclusion&#xD;
             criterion).&#xD;
&#xD;
          -  Exam evidence of external ocular infection, including conjunctivitis, chalazion, or&#xD;
             significant Blepharitis.&#xD;
&#xD;
          -  Systemic Exclusion Criteria: A subject is not eligible if any of the following&#xD;
             exclusion criteria are present:&#xD;
&#xD;
          -  Significant renal disease, defined as a history of chronic renal failure requiring&#xD;
             dialysis or kidney transplant.&#xD;
&#xD;
          -  A condition that, in the opinion of the investigator, would preclude participation in&#xD;
             the study (e.g., unstable medical status including blood pressure, cardiovascular&#xD;
             disease, and glycemic control).&#xD;
&#xD;
          -  Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110).&#xD;
&#xD;
          -  Major surgery within 28 days prior to randomization or major surgery planned during&#xD;
             the next 6 months.&#xD;
&#xD;
          -  Myocardial infarction, other cardiac event requiring hospitalization, stroke,&#xD;
             transient ischemic attack, or treatment for acute congestive heart failure within 6&#xD;
             months prior to randomization.&#xD;
&#xD;
          -  Systemic anti-vascular growth factor (ranibizumab) or pro-VEGF treatment within 4&#xD;
             months.&#xD;
&#xD;
          -  For women of childbearing potential: pregnant or lactating or intending to become&#xD;
             pregnant within the next 12 months.&#xD;
&#xD;
          -  Subject is expecting to move out of the area of the clinical center to an area not&#xD;
             covered by another clinical center during the study.&#xD;
&#xD;
          -  The target eye is the only eye of the subject, with the fellow eye's visual acuity&#xD;
             lower than 1.3 LogMAR units.&#xD;
&#xD;
          -  Baseline logMAR BCVA from 0.05 to 0.5 (Snellen)&#xD;
&#xD;
          -  Fellow eye BCVA 0.05 or worse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Wong, FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. WONG Yat-hin Ian</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic Macula Edema</keyword>
  <keyword>End-Point-Management</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

